Zacks: Brokerages Anticipate CareDx Inc (CDNA) Will Post Quarterly Sales of $11.96 Million
Equities research analysts expect CareDx Inc (NASDAQ:CDNA) to announce sales of $11.96 million for the current quarter, Zacks reports. Three analysts have provided estimates for CareDx’s earnings, with the lowest sales estimate coming in at $11.77 million and the highest estimate coming in at $12.11 million. CareDx reported sales of $10.86 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 10.1%. The firm is scheduled to announce its next earnings results on Friday, April 20th.
According to Zacks, analysts expect that CareDx will report full year sales of $11.96 million for the current fiscal year, with estimates ranging from $47.59 million to $47.93 million. For the next financial year, analysts anticipate that the business will report sales of $62.47 million per share, with estimates ranging from $59.80 million to $64.45 million. Zacks’ sales averages are a mean average based on a survey of analysts that that provide coverage for CareDx.
CareDx (NASDAQ:CDNA) last issued its quarterly earnings data on Thursday, November 9th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.02. The company had revenue of $12.19 million for the quarter, compared to analyst estimates of $12.05 million. CareDx had a negative return on equity of 157.00% and a negative net margin of 84.14%. The business’s revenue was down 2.3% on a year-over-year basis.
CareDx (NASDAQ CDNA) opened at $7.10 on Friday. The stock has a market capitalization of $200.23, a PE ratio of -3.92 and a beta of 1.05. CareDx has a twelve month low of $0.76 and a twelve month high of $7.98. The company has a current ratio of 0.55, a quick ratio of 0.35 and a debt-to-equity ratio of -124.53.
In related news, COO Mitchell J. Nelles sold 10,948 shares of the firm’s stock in a transaction dated Thursday, November 30th. The stock was sold at an average price of $7.17, for a total transaction of $78,497.16. Following the transaction, the chief operating officer now owns 84,225 shares of the company’s stock, valued at $603,893.25. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider James P. Yee sold 29,197 shares of the firm’s stock in a transaction dated Friday, December 8th. The stock was sold at an average price of $7.00, for a total value of $204,379.00. Following the transaction, the insider now directly owns 74,795 shares in the company, valued at approximately $523,565. The disclosure for this sale can be found here. Company insiders own 5.40% of the company’s stock.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Private Wealth Partners LLC grew its holdings in shares of CareDx by 2,250.0% during the third quarter. Private Wealth Partners LLC now owns 235,000 shares of the company’s stock worth $869,000 after buying an additional 225,000 shares during the last quarter. Gagnon Securities LLC lifted its position in CareDx by 3.9% in the third quarter. Gagnon Securities LLC now owns 2,166,403 shares of the company’s stock valued at $8,016,000 after purchasing an additional 82,111 shares during the period. Thompson Davis & CO. Inc. lifted its position in CareDx by 3,294.9% in the third quarter. Thompson Davis & CO. Inc. now owns 203,692 shares of the company’s stock valued at $754,000 after purchasing an additional 197,692 shares during the period. Perkins Capital Management Inc. acquired a new stake in CareDx in the third quarter valued at about $513,000. Finally, Royce & Associates LP lifted its position in CareDx by 8.1% in the third quarter. Royce & Associates LP now owns 792,787 shares of the company’s stock valued at $2,933,000 after purchasing an additional 59,500 shares during the period. 23.14% of the stock is currently owned by hedge funds and other institutional investors.
CareDx, Inc is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company’s commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.